



## รายงานวิจัยฉบับสมบูรณ์

โครงการการศึกษาพันธุกรรมและคุณลักษณะของไวรัส  
ซิคูนกunyaที่มีการปรับตัวเข้ากับเซลล์เพาะเลี้ยง

โดย ดร.รจนกร พูลมานะอุสาทะกุล

สิงหาคม ๒๕๕๘

สัญญาเลขที่ MRG5480128

รายงานวิจัยฉบับสมบูรณ์

โครงการการศึกษาพันธุกรรมและคุณลักษณะของไวรัส  
ซึ่คุณกุนยาที่มีการปรับตัวเข้ากับเซลล์เพาะเลี้ยง

ดร.รจนกร พูลมานะอุสาหะกุล  
สถาบันชีววิทยาศาสตร์โมเลกุล  
มหาวิทยาลัยมหิดล

สนับสนุนโดยสำนักงานกองทุนสนับสนุนการวิจัย

(ความเห็นในรายงานนี้เป็นของผู้วิจัย  
สกว. ไม่จำเป็นต้องเห็นด้วยเสมอไป)

## Abstract

---

**Project Code :** MRG5480128

**Project Title :** Genetic and phenotypic characterization of tissue cultured-adapted chikungunya viruses

**Investigator :** Rojjanaporn Pulmanusahakul  
Institute of molecular biosciences, Mahidol University

**E-mail Address :** rojjanaporn.pul@mahidol.ac.th

**Project Period :** 15 มิถุนายน 2554 –  
(ระยะเวลาโครงการ)

Chikungunya virus (CHIKV), a mosquitoes-borne *Alphavirus*, is an etiological agent of chikungunya fever. The virus is an enveloped positive single stranded RNA virus. In 2005-2006, CHIKV re-emerged and caused the major outbreak started from the Indian Ocean islands and spread to many countries in Asia including Thailand. In this project, the whole genome of CHIKV isolated from a Thai patient was sequenced. The results showed the virus belongs to the East Central South African (ECSA) genotype with an alanine to valine substitution at position 226 of the E1 protein, which is consistent with other isolates in the same outbreak. The CHIKV isolates was then undergone through two independent plaque purification series in Vero and C6/36 cells, resulting in the viruses that produced large and small plaque size, respectively. The viruses exhibited different levels of pathogenicity after intracranially infected to suckling mice in which the large plaque virus is highly pathogenic whereas the small plaque virus is almost non-pathogenic. Comparison of the genetic sequences of the Vero adapted-virus and parental isolates revealed 3 amino acid differences, nsP2: P618R, nsP3: G117R and E2: N187K, while the C6/36 adapted-virus differ from the parental virus only one position at nsP2: D546G.

**Keywords:** Chikungunya virus, Thai isolate, Tissue culture-adaptation, Plaque purification, Viral pathogenicity

**ชื่อโครงการ:** การศึกษาพันธุกรรมและคุณลักษณะของไวรัสชิคุนกุนยาที่มีการปรับตัวเข้ากับเซลล์เพาะเลี้ยง

ไวรัสชิคุนกุนยาเป็นสาเหตุของโรคไข้วัดข้อชิคุนกุนยาซึ่งมีอยู่เป็นพาหะ ไวรัสนี้จัดอยู่ในวงศ์ *alphavirus* ซึ่งเป็นไวรัสที่มีเปลือกหุ้มและมีจีโนมเป็นอาร์เอ็นเอสายบวก ในช่วงปีค.ศ. 2005 ถึง 2006 ได้เกิดการระบาดของไวรัสชิคุนกุนยารั้งใหญ่ โดยเริ่มเกิดขึ้นที่หมู่เกาะในมหาสมุทรอินเดีย และแพร่ระบาดมาจนถึงทวีปเอเชีย รวมทั้งประเทศไทย ซึ่งโครงการนี้ได้ทำการศึกษาไวรัสชิคุนกุนยาที่แยกได้จากผู้ป่วยในประเทศไทย โดยทำการหาลำดับเบสทั้งจีโนมของไวรัส หลังจากนำผลที่ได้มาทำการเปรียบเทียบกับฐานข้อมูล พบว่าไวรัสนี้จัดอยู่ในกลุ่ม ECSA และมีการเปลี่ยนแปลงกรดอะมิโนที่ตำแหน่ง 226 ของโปรตีน E1 จาก alanine เป็น valine ซึ่ง สอดคล้องกับผลของผู้วิจัยอื่นที่ทำการศึกษาไวรัสชิคุนกุนยาจากการระบาดครั้งเดียวกันนี้ จากนั้นผู้วิจัยได้นำไวรัสชิคุนกุนยานี้ไปเลี้ยงในเซลล์ไตลิง (Vero) และมาทำให้บริสุทธิ์ด้วยวิธีการเลือก plaque ขนาดใหญ่ หรือเลี้ยงในเซลล์ยูง (C6/36) แล้วเลือก plaque ขนาดเล็ก โดยไวรัสที่มีลักษณะ plaque ต่างกันนี้แสดงควมรุนแรงต่างกันหลังจากฉีดเข้าสมองหนูแรกเกิด ไวรัสที่สร้าง plaque ขนาดใหญ่มีความรุนแรงมาก ในขณะที่ไวรัสที่สร้าง plaque ขนาดเล็กเกือบจะไม่มีอันตรายต่อหนู เมื่อเปรียบเทียบลำดับเบสของไวรัสทั้งสองกับไวรัสต้นแบบที่แยกจากผู้ป่วย พบว่าไวรัสที่สร้าง plaque ใหญ่มีการสร้างกรดอะมิโนแตกต่างจากไวรัสต้นแบบ 3 ตำแหน่ง คือ ที่โปรตีน nsP2 ตำแหน่ง 618 จากโปรตีนเป็นอาร์จีนีน ที่โปรตีน nsP3 ตำแหน่ง 117 จากไกลซีนเป็นอาร์จีนีน และที่โปรตีน E2 ตำแหน่ง 187 จากแอสพาราจีนเป็นไลซีน ส่วนไวรัสที่สร้าง plaque ขนาดเล็กมีความแตกต่างจากไวรัสต้นแบบแค่ หนึ่งตำแหน่งที่ 546 ของโปรตีน nsP2 จากกรดแอสพาทิกเป็นไกลซีน



## Executive summary MRG5480128

### ชื่อโครงการ

(ภาษาไทย) การศึกษาพันธุกรรมและคุณลักษณะของไวรัสชิคุนกุนยาที่มีการปรับตัวเข้ากับเซลล์เพาะเลี้ยง

(ภาษาอังกฤษ) Genetic and phenotypic characterization of tissue cultured-adapted chikungunya viruses

### ชื่อหัวหน้าโครงการ

(ภาษาไทย) นางสาว รจนกร พูลมานะอุสาหะกุล

(ภาษาอังกฤษ) Miss Rojjanaporn Pulmanusahakul

(ตำแหน่งวิชาการ) อาจารย์

### สถานที่ติดต่อ

ที่ทำงาน สถาบันชีววิทยาศาสตร์โมเลกุล มหาวิทยาลัยมหิดล  
25/25 หมู่ 3 ถ.พุทธมณฑล สาย 4 ต.ศาลายา อ.พุทธมณฑล จ.นครปฐม 73170  
โทรศัพท์ 02-441-9003-7 ต่อ 1479  
email rojjanaporn.pul@mahidol.ac.th

### ชื่อนักวิจัยที่ปรึกษา

(ภาษาไทย) นายประเสริฐ เอื้อวรากุล

(ภาษาอังกฤษ) Mister Prasert Auewarakul

(ตำแหน่งวิชาการ) ศาสตราจารย์

### สถานที่ติดต่อ

ที่ทำงาน สถาบันชีววิทยาศาสตร์โมเลกุล มหาวิทยาลัยมหิดล  
25/25 หมู่ 3 ถ.พุทธมณฑล สาย 4 ต.ศาลายา อ.พุทธมณฑล จ.นครปฐม 73170  
โทรศัพท์ 02-441-9003  
โทรสาร 02-441-1013  
email prasert.aue@mahidol.ac.th

### ชื่ออธิการบดี หรือผู้รับมอบอำนาจให้ลงนามแทนอธิการบดี

ศาสตราจารย์คลินิก นายแพทย์อุดม คชินทร

## 1. ความสำคัญและที่มาของปัญหาที่ทำการวิจัย

Chikungunya is the dengue-like illness that produces a high fever, myalgia, skin rashes, severe and sometimes prolonged arthritis. Although it originated in Africa, chikungunya became epidemic throughout Asia including Thailand. Recently, the 2005-2006 massive outbreak of chikungunya in La Reunion Islands lead to 270,000 infected cases and more than a million cases were reported all over Asia in 2007. The situation of chikungunya outbreak in Thailand became more significant in the October of 2008. By the end of 2009, the total of 49,000 confirmed cases were reported throughout the country, particularly in the South. Unlike the prior outbreaks that caused by the Asian genotype of chikungunya virus, the severity of the disease in this most recent outbreak, which caused by the ECSA genotype with A226V mutation, was shown to be elevated. Hence, a better understanding about the pathogenicity of the virus is a great concern, as ultimately, it might lead to a chikungunya vaccine development that is still unavailable at present. Serially passages of the virus in non-natural host cells can lead to the virus-host adaptation.

## 2. วัตถุประสงค์

1. To obtain the complete genomic sequence of wild-type clinical isolate of chikungunya virus and perform phylogenetic analysis.
2. To obtain tissue culture-adapted chikungunya viruses that produce homogenous large or small plaques.
3. To genotypically and phenotypically characterize tissue culture-adapted chikungunya viruses in comparison to wild-type chikungunya virus and identify tentative genotypic markers of the plaque morphologies.

## 3. ระเบียบวิธีวิจัย

### *Complete genomic sequencing of clinical isolated virus*

The wild-type virus, isolated from the patient from Phang-nga, was kindly given from Professor Sukathida Ubol, faculty of science, Mahidol University. Viral RNA was extracted using Trizol and used for first strand cDNA synthesis. Nine overlapping fragments covering the entire genome were amplified and cloned into sequencing plasmids. 5'end of the genome was amplified using RACE PCR. The sequences from 3 clones of each fragment were aligned to determine the consensus sequence. Then, the sequences of 9 fragments were joined to construct the complete genomic sequence.

### ***Tissue culture-adapted viruses***

Tissue cultured-adapted CHIKVs derived from several passages of viral propagation and plaque purified in suitable cell-lines. Vero cells were used for large plaque purification while C6/36 cells were used to select small plaque virus. Wild-type CHIKV was used in plaque assay and large or small plaques from terminal dilution were picked by using sterile pipette tips, suspended in serum-free medium and inoculated directly onto the Vero or C6/36 cells, respectively. The recovered viruses were harvested when CPE was observed. Plaque purifications were done several times until homogenous small or large size plaques were obtained.

### ***In vitro characterization***

Plaque morphologies of tissue cultured-adapted CHIKVs in comparison to wild-type virus were determined by standard plaque assay using Vero cells. The growth kinetics of the viruses was studied in C6/36 cells.

### ***In vivo characterization***

Mouse neurovirulent assay were performed to study the pathogenicities of the viruses. Groups of suckling mice were intracranially infected with wild-type or tissue cultured-adapted viruses and monitored for the survival for 21 days.

### ***Determination of genotypic markers of plaque morphology***

The whole genome sequencing of tissue cultured-adapted viruses were performed and the results were compared to that of wild-type virus to determine the tentative genotypic markers. The mutations were confirmed in 2 additional clones.

## **4. ผลการทดลอง**

In this project, the whole genome of chikungunya virus (CHIKV) isolated from a Thai patient, WT-CHK025, was sequenced. The results showed the viral genome is 11,811 nucleotides in length. The virus belongs to the East Central South African (ECSA) genotype with an alanine to valine substitution at position 226 of the E1 protein, which is consistent with other isolates in the same outbreak. The CHIKV isolate was then undergone through two independent plaque purification series in Vero and C6/36 cells, resulting in the viruses that produced large and small plaque size, respectively. The viruses exhibited different levels of pathogenicity after intracranially infected to suckling mice in which the large plaque virus is highly pathogenic whereas the small plaque virus is almost non-pathogenic. Comparison of the genetic sequences of the Vero adapted-virus and parental isolates revealed 3 amino acid differences, nsP2: P618R, nsP3: G117R

and E2: N187K, while the C6/36 adapted-virus differ from the parental virus only one position at nsP2: D546G.

## 5. Output

อยู่ระหว่างการเตรียม manuscript สำหรับตีพิมพ์ในวารสารวิชาการระดับนานาชาติ โดยชื่อเรื่องที่กำลังจะตีพิมพ์คือ Genetic and phenotypic characterization of tissue cultured-adapted chikungunya viruses.

## วัตถุประสงค์

1. To obtain the complete genomic sequence of wild-type clinical isolate of CHIKV and perform phylogenetic analysis.
2. To obtain tissue culture-adapted CHIKVs that produce homogenous large or small plaques.
3. To genotypically and phenotypically characterize tissue culture-adapted CHIKVs in comparison to wild-type CHIKV and identify tentative genotypic markers of the plaque morphologies.

## วิธีทดลอง

### Cells and viruses:

C6/36 cells, an *Aedes albopictus* larvae cells, were maintained at 28°C in minimum essential medium (MEM; Gibco, CA, USA) supplemented with 10% heat inactivated fetal bovine serum (FBS; Gibco, CA, USA or HyClone, Cramlington, UK) and 100 unit of penicillin/streptomycin per ml. Vero cells, African green monkey kidney epithelial cells, and MRC-5 cells, human lung fibroblast, were maintained at 37 °C, 5% CO<sub>2</sub> in Dulbecco's modified Eagles medium (DMEM; Gibco, CA, USA) supplemented with 5% FBS and 100 unit of penicillin/streptomycin per ml.

CHIKV was kindly given from Prof. Sukathida Ubol, Department of Microbiology, Faculty of Science, Mahidol University. The virus was isolated from a patient in Phangnga, Thailand in 2009 and passaged two times in C6/36 cells. The virus was designated as WT-CHK025. CHIKV stock was propagated in C6/36 cells. The culture medium and the infected cells was harvested at 40 hr after infection and stored at -80 °C until use.

### Standard plaque assay:

Vero cells were used for the plaque assay since they display distinct cytopathic effect (CPE). The cells were seeded in 6 wells plate with DMEM, supplemented with 5% heat inactivated FBS. Viruses were 10-fold serially diluted in BA-1 medium (1xM-199E, 1 M Tris-HCl pH 7.6, 2% (w/v) BSA, 100 units of penicillin/streptomycin per ml, 0.075% (w/v) NaHCO<sub>3</sub>) and 200 µl of each dilution was used to infect 90-95% confluent of monolayer Vero cells. The plates were incubated and rocked every 10 min for 2 hr at 37 °C. After that, each well was overlaid with 4 ml of nutrient agarose [0.8% agarose (SeaKem LE, USA) containing Earle's balanced salts supplemented with 0.5% (w/v) yeast extract, 2.5% lactalbumin hydrolysate, 3% FBS] and incubated at 37°C, 5% CO<sub>2</sub> for 3 or 6 days until plaque formation. The cell layer was stained with the second

overlay containing 1% neutral red and incubated as above condition for 16 hr for plaque observation. To determine virus titers, plaque assay was done in duplicated. The plaques were counted and calculated as plaque forming unit per ml (pfu/ml).

#### Tissue cultured-adapted viruses:

Tissue cultured-adapted CHIKV derived from several passages of viral propagation and plaque purified in suitable cell-lines. Vero cells were used for large plaque purification while C6/36 cells were used to select small plaque virus. WT-CHK025 was used in plaque assay and large or small plaques from terminal dilution were picked by using sterile pipette tips, suspended in serum-free medium and inoculated directly onto the Vero or C6/36 cells, respectively. The recovered viruses were harvested when CPE was observed. Plaque purifications were done several times until homogenous small or large size plaques were obtained.

For Vero-adapted CHIKV, isolated CHIKV was propagated three times in C6/36 cells and two times in Vero cells (WT-CHK025 passage 5), followed by 6 plaque purifications alternated with propagation in Vero cells for the total of 17 passages. The virus showed homogenous large plaque morphology and was designated as CHK-L.

To obtain CHIKV with small plaque morphology, the process was started with WT-CHK025 passage 4 (isolated CHIKV that propagated two times in C6/36 cells and two times in Vero cells). Plaque assay was performed to separate small plaques. One clone of transferred small plaque virus was propagated in three different monolayer cell lines; Vero, MRC-5 and C6/36 to select optimum cell line for small plaque purification and C6/36 was selected. Plaque purifications were continued two times in Vero cells alternated with three times virus propagation in C6/36. Finally, homogenous small plaque morphology was observed after three times plaque purification and total 14 times viral propagations. This virus was designated as CHK-S.

#### Virus growth kinetics:

Monolayer of C6/36 cells were infected with CHK-L or CHK-S at MOI of 5. The viruses were adsorbed at room temperature for 2 hours. Then the cells were washed with PBS for 3 times and maintained in fresh media at 37°C with 5% CO<sub>2</sub>. Supernatants of infected cells were collected every 6 hours post-infection (hpi) until 48 hpi. The titers of the infectious viruses were determined by standard plaque assay using Vero cells.

#### Mouse Neurovirulence:


This study was kindly performed by the Center for Vaccine Development, Institute of Molecular Biosciences, Mahidol University. Three groups of suckling mice (>24 to 72 hr-old), 50, 55 and 45 mice/group, were intracranially injected (i.c.) with 10<sup>3</sup> pfu of WT-CHK025, CHK-S or CHK-L, respectively. The mice were observed daily for

21 days. The results were used to plot the survival curves and calculate for average survival times.

RNA extraction, cDNA synthesis and PCR

RNA was extracted from the supernatant or cell lysate of CHIKV passage 2 infected cells using Trizol reagent (Invitrogen, USA.) following the manufacturer’s protocol. The RNA was resuspended in 50 µl of DEPC-treated water. One µg of RNA was reverse transcribed using Improm II™ reverse transcriptase and random hexamer or oligo-dT as a primer (Promega, USA.).

To design specific primers for PCR, several sequences of CHIKV isolates were aligned to get the consensus sequence using clustalW web online. Nine primer pairs were designed to amplify 9 overlapping fragments covering the entire 12 kb of CHIKV genome using ApE (Davis M. W.: <http://www.biology.utah.edu/jorgensen/wayned/apex/>) and Primers3 (Lincoln S., et al.: <http://frodo.wi.mit.edu/primer3/>) v.0.4.0. software (figure 1). Some primers were synthesized following the paper from E.Sreekumar, et al.,2010. Table 1 shows sequences and priming positions of the primer pair for each fragment.



**Figure 1:** PCR primer pairs were designed to amplify nine overlapping fragments covering the entire 12 kb of CHIKV genome.

The cDNA was amplified by PCR with the following reaction mixture; cDNA, 1X buffer (20mM Tris-HCL (pH 8.4), 50 mM KCL), 1.5 mM MgCl<sub>2</sub>, 0.2 mM dNTP, 0.2 µM of each forward and reverse primers, 1U Platinum® Taq DNA polymerase and the volume was adjusted to 50 µl with ddH<sub>2</sub>O. The PCR condition is as follow;

94 °C	2 min	
94 °C	30 sec	} 35 cycles
52-60 °C	30 sec	
68 °C	2-3 min	
68 °C	7 min	

The amplified PCR products were analyzed by gel electrophoresis and purified with Gel/PCR DNA fragments extraction kit (Geneaid, Taipei, Taiwan) according to manufacturer's protocol.

**Table 1:** Primer pairs for amplifying 9 fragments of CHIKV genome

Fragment	Primers	Primer sequence (5'-3')	nt position
Fragment1	F:anchor primer	GAC CAC GCG TAT CGA TGT CGA CTT TTT TTT TTT TTT TT	-
	R:R889	ACG TAG CCC TCA CAC GAA ACC	913-993
Fragment2	F:chf2	CGT CTA TGC TGT ACA CGC A	532-549
	R:chr5	CGT CGT ACG CTT CGA CCG	1863-1880
Fragment3	F:chf4	GAC AGC TTT GTG GTA CCG A	1418-1436
	R:R3209	GGG CTA CTT CAG GTG ACT ATG	3213-3233
Fragment4	F:chf8	CCT ATC CTC GAA ACA GCG	3134-3151
	R:R4871	TGA CGC GTT CTG GAG TCA TA	4876-4895
Fragment5	F:chf12	GAA ATG CCC GGT GGA TGA	4807-4824
	R:chr17	ACG CGG ATT TTG TCA GAC G	7025-7043
Fragment6	F:chf16	ATA CAG GCG GCT GAA CCC T	6599-6617
	R:chr20	GAT GGC AAG ACT CCA CTC T	8343-8361
Fragment7	F:K5F	CTC GGT GGT GAC CTG GAA TA	8286-8305
	R:K5R	TGT TGG CTC CAA AGT GAC TG	10097-10116
Fragment8	F:E1F	AAA CAT ATG TAC GAA CAC GTA ACA G	9994-10009
	R:E1R	AAA GGA TCC GTG CCT GCT GAA CGA CA	11294-11313
Fragment9	F:E1(10564)	GGC GCC TAC TGC TTC TG	10564-10582
	R:oligo dT	Oligo dT (16 mer)	-



The 5' end of the viral RNA was amplified using 5'/3' RACE, 2<sup>nd</sup> Generation Kit (Roche, Switzerland) following the manufacturer's instruction. Briefly, the RNA was reverse transcribed using specific primer chr5. RT reaction mixture was composed of 1xcDNA synthesis buffer, 0.5 mM dNTP, 12.5  $\mu$ M chr5 primer, RNA 0.2-2  $\mu$ g, 1 unit Transcriptor reverse transcriptase enzyme and DEPC-water up to 20  $\mu$ l. RT reaction was incubated at 55 °C for 60 minutes followed by additionally incubation at 85 °C for 5 minutes. The cDNA product was purified by High pure PCR product Purification kit (Roche, Switzerland) according to the manufacturer's protocol. After that, a homopolymeric A-tail was added to the 3'end of purified cDNA product using recombinant terminal transferase enzyme. The reaction mixture (1xbuffer, 0.2 mM dATP and purified cDNA up to 24  $\mu$ l) was incubated at 94 °C for 3 minutes and immediately chilled on ice. Then 1 $\mu$ l of 80 unit/ $\mu$ l terminal transferase enzyme was added into the reaction and incubated at 37 °C for 30 minutes. Finally, the enzyme was heat inactivated at 70 °C for 10 minutes. The dA-tail cDNA was amplified using oligo d(T) anchor primer and specific primers R889 using Platinum<sup>®</sup> Taq DNA polymerase enzyme with the condition described above. The PCR product was monitored by gel electrophoresis and purified by Gel/PCR DNA fragments extraction kit.

#### Cloning and sequencing

Each purified PCR fragment was cloned into the sequencing vector. Fragments 1-5 were cloned into p-SC-A vector (Takara, Japan) while fragments 6-8 were cloned into pCR<sup>®</sup>2.1vector (Invitrogen, USA.) and fragment 9 was cloned into pCR4-TOPO vector (Invitrogen, USA.).

Since the PCR fragment was amplified with Taq DNA polymerase, it can be directly cloned into the pCR<sup>®</sup>2.1 vector using TA cloning technique. The purified PCR product was ligated to the vector using T4 DNA ligase enzyme. The ligation reaction was composed of 1x ligation buffer (6 mM Tris-HCl, pH 7.5, 6 mM MgCl<sub>2</sub>, 5 mM NaCl, 0.1 mg/ml bovine serum albumin, 7 mM  $\beta$ -mercaptoethanol, 0.1 mM ATP, 2 mM dithiothreitol and 1 mM spermidine), 2  $\mu$ l of pCR<sup>®</sup>2.1 vector (25 ng/ $\mu$ l plasmid DNA in 10 mM Tris-HCl, 1 mM EDTA, pH 8), 50 ng of purified PCR product, sterile-water up to 9  $\mu$ l and 1  $\mu$ l of 1unit/ $\mu$ l T4 DNA ligase. Then, this reaction was incubated at 16 °C for overnight.

The PCR products were cloned into pCR4-TOPO and p-SC-A vectors using Topoisomerase I enzyme, which covalently bound to the vector. Therefore, the ligation reaction was incubated at room temperature for only 5 min. In detail, the ligation reaction of pCR4-TOPO vector was composed of 0.5-4.0  $\mu$ l of purified PCR product (about 10-50 ng), 1  $\mu$ l of salt solution (1.2 M NaCl, 0.06 M MgCl<sub>2</sub>) and 1 $\mu$ l of pCR4-TOPO vector (10 ng/ $\mu$ l plasmid DNA in 50% glycerol, 50 mM Tris-HCl pH 7.4, 1 mM

EDTA, 2 mM DTT, 0.1% Triton X-100, 100 µg/ml BSA and 30 µM phenol red). The p-SC-A ligation reaction was composed of 3 µl of StrataClone Cloning buffer, 2 µl of purified PCR product (5-50 ng) and 1 µl of StrataClone vector. The ligation reaction was mixed gently by pipetting and incubated as described. When the incubation was completed, the reaction was placed on ice.

Every ligation product was transformed into *Escherichia coli* DH5 $\alpha$  competent cells using heat-shock method at 42 °C for exactly 90 seconds. The transformant was grown on LB agar plate containing 100 ng/µl of ampicillin with 4 µl of 400 mM IPTG and 20 µl of 20 mg/ml X-gal. The bacterial colonies were initially screened using blue/white colony method. The white colonies were picked and cultured in LB broth containing 100 ng/µl of ampicillin at 37°C for 12-16 hr. Then, the plasmid DNA was extracted using High-speed plasmid mini kit (Geneaid, Taipei, Taiwan) and the insert fragment was confirmed by restriction enzymes digestion analysis.

Three clones of recombinant plasmids of each fragment were sequenced at Tech Dragon Limited (Hong Kong) and Macrogen (Korea). The plasmids were sequenced with two universal primers, M13F and M13R, and one specific internal primer with the exception of fragment 2 that was sequenced with only two specific PCR primers, chf2 and chr5. Finally, fragment 9 was sequenced with one universal primer at 3' end of this fragment. The sequences of the specific internal primers are shown in table 2. Three clones of recombinant plasmids of each fragment were aligned to confirm and generate the consensus sequence. Then the sequences of 9 fragments were combined to reconstruct the whole CHIKV genome using BioEdit Sequence Alignment Editor Program (version 7.0.5.3). The CHIKV nucleotide and amino acid sequence were subjected to the phylogenetic analysis using CLC program based on complete genome sequences.

**Table 2: Sequencing primers**

Fragment	Sequencing primers	Primer sequence (5'-3')	nt position
Fragment1	R: Chr2	TGC GTG TAC AGC ATA GAC G	532-549
Fragment3	R: Chr5	CGT CGT ACG CTT CGA CCG	1863-1880
Fragment4	F: FS3584	AAC CTT GCA CTG CCT ACT AAG AGA G	3608-3632
Fragment5	F: FS5229	TAA TGA GCA CCG TAG CTG TC	5253-5272
Fragment6	R: Chr19	ACC TTC GTG CTT GAC TTC G	7911-7929
Fragment7	F: FS8793	GAT TAC TGG AAC AAT GGG ACA C	8817-8838
Fragment8	F: E1F10564	CCC TTT GGC GCA GGA AGA C	10564-10582


The sequences of CHK-L and CHK-S were obtained from RT-PCR directly. The viral RNAs were extracted, cDNAs were generated and then 9 fragments were amplified by PCR using the primer pairs shown in table 1. The products were sequenced using the same PCR primers excepted fragment 9 that was cloned and sequenced with universal primer. The sequences of plaque-purified viruses were reconstructed the same as those of WT-CHK025.

To identify the tentative genotypic markers for plaque morphologies, the sequences of CHK-L and CHK-S were compared to WT-CHK025 sequence using BioEdit Sequence Alignment Editor software. The differences were confirmed with two others plaque purified CHIKV clones.

## ผลการทดลอง

### Complete genomic sequencing of wild type CHIKV isolates 025

To sequence the genome of WT-CHK025, nine overlapping fragments covering the entire 12 kb were amplified by RT-PCR as described earlier. Figure 2 shows the result of agarose gel electrophoresis of all 9 fragments.



**Figure 2:** Agarose gel electrophoresis of the RT-PCR products of fragment 1-9 of CHIKV genome. The sizes are about 1, 1.3, 1.8, 1.8, 2.2, 1.8, 1.8, 1.3 and 1.3 kb, respectively. M: DNA marker; lane1-9: RT-PCR products of fragment 1-9.

The products of each fragment were cloned into sequencing vectors and checked by restriction enzyme digestion analysis. Three clones of recombinant plasmids of each fragment were sequenced and aligned to determine the consensus sequence and reconstructed to obtain complete genomic sequence of WT-CHK025. The result was submitted to GenBank, NCBI. The accession number is KP164869.

The size of the entire genome of WT-CHK025 is 11,811 bp with the 5' and 3' NTR of 76 and 498 bp, respectively. The length of the first open reading frame (ORF) is

7,422 nucleotides while the second ORF is 3,747 nucleotides. In addition, there is a 68 nucleotide-untranslated junction between the two ORFs.

The first ORF comprises four non-structural genes; nsP1 to nsP4, which are 1,605, 2,394, 1,590, and 1,833 nucleotides in length, respectively. After being translated and proteolytically cleaved, the sizes of nsP1-4 are 535, 798, 529 and 611 amino acids, respectively. At C-terminal of nsP3, there is an opal stop codon (UGA) at nucleotide position 5,645-5,647. The second ORF consists of capsid, E3, E2, 6k and E1 genes, which are 783, 192, 1,269, 138 and 1,320 nucleotides long or 261, 64, 423, 46 and 440 amino acids after being expressed, respectively. The amino acid at position 226 of E1 protein is valine, which is hypothesized to affect the vector specificity that responsible for this massive outbreak. At the 3'end, there are poly (A) tracts and 19-nucleotides of conserved sequence element (CSE), 5'-AUUUUGUUUUUAAUAUUC-3', which is conserved among alphavirus. Moreover, 3'NTR contains three repeats sequence elements (RSEs) at nucleotides position 11,384-11,418, 11,513-11,547 and 11,598-11,632. The whole genome sequence of WT-CHK025 is shown in figure 3.

1	ATGGCTGCGT	GAGACACACG	TAGCCTACCA	GTTTCTTACT	GCTCTACTCT	GCAAAGCAAG
61	AGATTAATAA	CCCATCA	TGG	ATCCTGTGTA	CGTGGACATA	GACGCTGACA
121	GAAGGCCCTG	CAACGTGCGT	ACCCCATGTT	TGAGGTGGAA	TCAAGGCAGG	TCACACCGAA
181	TGACCATGCT	AATGCTAGAG	CGTTCTCGCA	TCTAGCTATA	AAACTAATAG	AGCAGGAAAT
241	TGACCCCGAC	TCAACCATCC	TGGATATCGG	CAGTGCGCCA	GCAAGGAGGA	TGATGTCGGA
301	CAGGAAGTAC	CACTGCGTCT	GCCCGATGCG	CAGTGCGGAA	GATCCCGAGA	GACTCGCTAA
361	TTATGCGAGA	AAGCTAGCAT	CTGCCGCAGG	AAAAGTCCTG	GACAGAAACA	TCTCTGAAA
421	GATCGGGGAC	TTACAAGCAG	TAATGGCCGT	GCCAGACAAG	GAGACGCCAA	CATTCTGCTT
481	ACACACAGAC	GTCTCATGTA	GACAGAGAGC	AGACGTCGCT	ATATACCAAG	ACGTCTATGC
541	TGTATACGCA	CCCACGTGCG	TATACCACCA	GGCGATTAAA	GGGGTCCGAG	TGGCGTACTG
601	GGTTGGGTTT	GACACAACCC	CGTTCATGTA	CGATGCCATG	GCGGGTGCCT	ACCCCTCATA
661	CTCGACAAAC	TGGGCAGATG	AGCAGGTACT	GAAGGCTAAG	AACATAGGAT	TATGTTCAAC
721	AGACCTGACG	GAAGGTAGAC	GAGGCAAGTT	GTCTATTATG	AGAGGGAAAA	AGCTAAAAACC
781	GTGCGACCGT	GTGCTGTTCT	CAGTAGGGTC	AACGCTCTAC	CCGGAAAGCC	GCAAGCTACT
841	TAAGAGCTGG	CACCTGCCAT	CGGTGTTCCA	TTTAAAGGGC	AAACTCAGCT	TCACATGCCG
901	CTGTGATACA	GTGGTTTCGT	GTGAGGGCTA	CGTCGTTAAG	AGAATAACGA	TGAGCCCAGG
961	CCTTTATGGA	AAAACCACAG	GGTATGCGGT	AACCCACCAC	GCAGACGGAT	TCCTGATGTG
1021	CAAGACTACC	GACACGGTTG	ACGGCGAAAG	AGTGTCATTC	TCGGTGTGCA	CATACGTGCC
1081	GGCGACCATT	TGTGATCAAA	TGACCGGCAT	CCTTGCTACA	GAAGTCACGC	CGGAGGATGC
1141	ACAGAAAGCTG	TTGGTGGGGC	TGAACCAGAG	AATAGTGTTT	AACGGCAGAA	CGCAACGGAA
1201	TATGAACACC	ATGAAAAATT	ATCTGCTTCC	CGTGGTCGCC	CAAGCCTTCA	GTAAGTGGGC
1261	AAAGGAGTGC	CGGAAAGACA	TGGAAGATGA	AAAACCTCTG	GGGGTCAGAG	AAAGAACACT
1321	GACCTGCTGC	TGTCTATGGG	CATTCAAGAA	GCAGAAAACA	CACACGGTCT	ACAAGAGGCC
1381	GGATACCCAG	TCAATTCAGA	AGGTTCAGGC	CGAGTTTGAC	AGCTTTGTGG	TACCGAGTCT
1441	GTGGTCGTCC	GGGTTGTCAA	TCCCTTTGAG	GACTAGAATC	AAATGGTTGT	TAAGCAAGGT
1501	GCCAAAAACC	GACCTGATCC	CATACAGCGG	AGACGCCCGA	GAAGCCCGGG	ACGCAGAAAA
1561	AGAAGCAGAG	GAAGAACGAG	AAGCAGAACT	GACTCGCGAA	GCCCTACCAC	CTCTACAGGC
1621	AGCACAGGAA	GATGTTTCAGG	TCGAAATCGA	CGTGGAAACAG	CTTGAGGACA	GAGCGGGCGC

1681	AGGAATAATA	GAGACTCCGA	GAGGAGCTAT	CAAAGTTACT	GCCCAACCAA	CAGACCACGT
1741	CGTGGGAGAG	TACCTGGTAC	TCTCCCCGCA	GACCGTACTA	CGTAGCCAGA	AGCTCAGTCT
1801	GATTACACGT	TTGGCGGAGC	AAGTGAAGAC	GTGCACGCAC	AACGGACGAG	CAGGGAGGTA
1861	TGCGGTCCGA	GCGTACGACG	GCCGAGTCCT	AGTGCCCTCA	GGCTATGCAA	TCTCGCCTGA
1921	AGACTTCCAG	AGTCTAAGCG	AAAGCGCAAC	GATGGTGAT	AACGAAAGAG	AGTTCGTAAA
1981	CAGAAAGCTA	CACCATATTG	CGATGCACGG	ACCAGCCCTG	AACACCGACG	AAGAGTCGTA
2041	TGAGCTGGTG	AGGGCAGAGA	GGACAGAACA	CGAGTACGTC	TACGACGTGG	ATCAGAGAAG
2101	ATGCTGTAAG	AAGGAAGAAG	CCGCAGGACT	GGTACTGGTG	GGCGACTTGA	CTAATCCGCC
2161	CTACCATGAA	TTCGCATATG	AAGGGCTAAA	AATCCGCCCT	GCCTGCCCAT	ACAAAATTGC
2221	AGTCATAGGA	GTCTTCGGAG	TACCGGGATC	TGGCAAGTCA	GCTATTATCA	AGAACCTAGT
2281	TACCAGGCAG	GACCTGGTGA	CTAGCGGAAA	GAAAGAAAAAC	TGCCAAGAAA	TCACCACCGA
2341	CGTGATGAGA	CAGAGAGGTC	TAGAGATATC	TGCACGTACG	GTTGACTCGC	TGCTCTTGAA
2401	TGGATGCAAC	AGACCAGTCG	ACGTGTTGTA	CGTAGACGAG	GCGTTTGCGT	GCCACTCTGG
2461	AACGCTACTT	GCTTTGATCG	CCTTGGTGAG	ACCAAGGCAG	AAAGTTGTAC	TTTGTGGTGA
2521	CCCGAAGCAG	TGCGGCTTCT	TCAATATGAT	GCAGATGAAA	GTCAACTATA	ATCACAACAT
2581	CTGCACCCAA	GTGTACCACA	AAAGTATCTC	CAGGCGGTGT	ACACTGCCTG	TGACCGCCAT
2641	TGTGTCATCG	TTGCATTACG	AAGGCAAAAT	GCGCACCACG	AATGAGTACA	ACAAGCCGAT
2701	TGTAGTGGAC	ACTACAGGCT	CAACAAAACC	TGACCCTGGA	GACCTCGTGT	TAACGTGCTT
2761	CAGAGGGTGG	GTAAACAAC	TGCAAAATTGA	CTATCGTGGA	TACGAGGTCA	TGACAGCAGC
2821	CGCATCCCAA	GGGTAAACCA	GAAAAGGAGT	TTACGCAGTT	AGACAAAAAG	TTAATGAAAA
2881	CCCCTCTAT	GCATCAACGT	CAGAGCACGT	CAACGTACTC	CTAACGCGTA	CGGAAGGTAA
2941	ACTGGTATGG	AAGACACTTT	CCGGCGACCC	GTGGATAAAG	ACGCTGCAGA	ACCCACCGAA
3001	AGGAACTTC	AAAGCAACTA	TTAAGGAGTG	GGAGGTGGAG	CATGCATCAA	TAACGGCGGG
3061	CATCTGCAAGT	CACCAAATGA	CCTTCGATAC	ATTCCAAAAT	AAAGCCAACG	TTTGTGGGCG
3121	TAAGAGCTTG	GTCCCTATCC	TCGAAACAGC	GGGGATAAAA	CTAAATGATA	GGCAGTGGTC
3181	TCAGATAAAT	CAAGCCTTCA	AAGAAGACAA	AGCATACTCA	CCTGAAGTAG	CCCTGAATGA
3241	AATATGTACG	CGCATGTATG	GGGTGGATCT	AGACAGCGGG	CTATTTTCTA	AACCGTCGGT
3301	GTCTGTGTAT	TACGCGGATA	ACCACTGGGA	TAATAGGCCCT	GGAGGGAAAA	TGTTCCGGATT
3361	TAACCCCGAG	GCAGCATCCA	TTCTAGAAAAG	AAAGTACCCA	TTCACAAAAG	GGAAGTGGAA
3421	CATCAACAAG	CAGATCTGCG	TGACTACCAG	GAGGATAGAA	GACTTTAACC	TAACCAACCA
3481	CATCATACCG	GCCAACAGGA	GACTACCACA	CTCATTAGTG	GCCGAACACC	GCCCAGTAAA
3541	AGGGGAAAGA	ATGGAATGGC	TGGTTAACAA	GATAAACGGC	CACCACGTGC	TCCTGGTCAG
3601	TGGCTATAAC	CTTGCACTGC	CTACTAAGAG	AGTCACTTGG	GTAGCGCCGT	TAGGTGTCCG
3661	CGGAGCGGAC	TACACATACA	ACCTAGAGTT	GGGTCTGCCA	GCAACGCTTG	GTAGGTATGA
3721	CCTTGTGGTC	ATAAACATCC	ACACACCTTT	TCGCATACAC	CATTACCAAC	AGTGCCTCGA
3781	CCACGCAATG	AAACTGCAAA	TGCTCGGGGG	TGACTCATTG	AGACTGCTCA	AACCGGGCGG
3841	CTCTCTATTG A	TCAGAGCAT	ATGGTTACGC	AGATAGAACC	AGTGAACGAG	TCATCTGCGT
3901	ATTGGGACGC	AAGTTTAGAT	CGTCTAGAGC	GTTGAAACCA	CCATGTGTCA	CCAGCAACAC
3961	TGAAATGTTT	TTCCTATTCA	GCAACTTTGA	CAATGGCAGA	AGGAATTTCA	CAACTCATGT
4021	CATGAACAAT	CAACTGAATG	CAGCCTTCGT	AGGACAGGTC	ACCCGAGCAG	GATGTGCACC
4081	GTCTGACCGG	GTAAAACGCA	TGGACATCGC	GAAAAACGAT	GAAAAAGTGCG	TAGTCAACGC
4141	CGTAACCCCT	CGCGGGTTAC	CGGGTGACGG	TGTTTGCAAG	GCAGTATACA	AAAAATGGCC
4201	GGAGTCCTTT	AAGAACAGTG	CAACACCAGT	GGGAACCGCA	AAAACAGTTA	TGTGTGGTAC
4261	GTATCCAGTA	ATCCACGCTG	TTGGACCAAA	CTTCTCTAAT	TATTCGGAGT	CTGAAGGGGA
4321	CCGGGAATTG	GCAGCTGCCT	ATCGAGAAGT	CGCAAAGGAA	GTAACCTAGG	TGGGAGTAAA
4381	TAGTGTAGCT	ATACCTCTCC	TCTCCACAGG	TGTATACTCA	GGAGGGAAAG	ACAGGCTGAC
4441	CCAGTCACTG	AACCACCTCT	TTACAGCCAT	GGACTCGACG	GATGCAGACG	TGGTCATCTA
4501	CTGCCGCGAC	AAAGAATGGG	AGAAGAAAAT	ATCTGAGGCC	ATACAGATGC	GGACCCAAGT
4561	AGAGCTGCTG	GATGAGCACA	TCTCCATAGA	CTGCGATATT	GTTGCGGTGC	ACCTGACAG
4621	CAGCTTGGA	GGCAGAAAAG	GATACGCAC	CACGGAAGGC	GCACTGTACT	CATATCTAGA
4681	AGGGACCCGT	TTTCATCAGA	CGGCTGTGGA	TATGGCGGAG	ATACATACTA	TGTGGCCAAA
4741	GCAAACAGAG	GCCAATGAGC	AAGTCTGCCT	ATATGCCCTG	GGGGAAAAGTA	TTGAATCTAT
4801	CAGGCAGAAA	TGCCCCGTGG	ATGATGCAGA	CGCATCATCT	CCCCCAAAA	CTGTCCCGTG
4861	CCTTTGCCGT	TACGCTATGA	CTCCAGAACG	CGTCACCCGG	CTTCGCATGA	ACCACGTCAC
4921	AAGCATAATT	GTGTGTTCTT	CGTTTCCCCT	CCCAAAGTAC	AAAATAGAAG	GAGTGCAAAA
4981	AGTCAAAATGC	TCTAAGGTAA	TGCTATTTGA	CCATAACGTG	CCATCGCGCG	TAAGTCCAAG
5041	GGAAATATAGA	TCTTCCCAGG	AGTCTGCACA	GGAGGCGAGT	ACAATCACGT	CTAGACGCA
5101	TAGTCAATTC	GACCTAAGCG	TTGATGGCGA	GATACTGCC	GTCCCGTCAG	ACCTGGATGC



5161	TGACGCCCCA	GCCCTAGAAC	CAGCACTAGA	CGACGGGGCG	ACACACACGC	TGCCATCCAC
5221	AACCGGAAAC	CTTGCGGCCG	TGTCTGACTG	GGTAATGAGC	ACCGTACCTG	TCGCGCCGCC
5281	CAGAAGAAGG	CGAGGGAGAA	ACCTGACTGT	GACATGTGAC	GAGAGAGAA	GGAATATAAC
5341	ACCCACGGCT	AGCGTCCGAT	TCTTTAGGGC	AGAGCTGTGT	CCGGTCGTAC	AAGAAACAGC
5401	GGAGACGCGT	GACACAGCAA	TGTCTCTTCA	GGCACCACCG	AGTACCGCCA	CGGAACCGAA
5461	TCATCCGCCG	ATCTCCTTCG	GAGCATCAAG	CGAGACGTTT	CCCATTACAT	TTGGGGACTT
5521	CAACGAAGGA	GAAATCGAAA	GCTTGTCTTC	T GAGCTACTA	ACTTTCGGAG	ACTTCTTACC
5581	AGGAGAAGTG	GATGACTTGA	CAGACAGCGA	CTGGTCCACG	TGCTCAGACA	CGGACGACGA
5641	GTTATGACTA	GACAGGGCAG	GTGGGTATAT	ATTCTCGTCG	GACACCGGTC	CAGGTCATTT
5701	ACAACAGAAG	TCAGTACGCC	AGTCAGTGCT	GCCGGTGAAC	ACCCTGGAGG	AAGTCCACGA
5761	GGAGAAGTGT	TACCCACCTA	AGCTGGATGA	AGCAAAAGGAG	CAACTATTAC	TTAAGAAACT
5821	CCAGGAGAGT	GCATCCATGG	CCAACAGAAG	CAGGTATCAG	TCGCGTAAAG	TAGAAAACAT
5881	GAAAGCAGCA	ATCATCCAGA	GAATAAAGAG	AGGCTGTAGA	CTATACTTAA	TGTCAGAGAC
5941	CCCAAAAGTC	CCTACTTACC	GGACTACATA	TCCGGCGCCT	GTGTACTCGC	CTCCGATCAA
6001	CGTCCGATTG	TCCAATCCCG	AGTCCGAGT	GGCAGCATGC	AATGAGTTCT	TAGCTAGAAA
6061	CTATCCAAC	GTCTCGTCAT	ACCAAATTAC	CGACGAGTAT	GATGCATATC	TAGACATGGT
6121	GGACGGGTCTG	GAGAGTTGCC	TGGACCGAGC	GACATTCAAT	CCGTCAAAAC	TCAGGAGCTA
6181	CCCGAAACAG	CACGCTTACC	ACGCGCCCTC	CATCAGAAGC	GCTGTACCGT	CCCCATTCCA
6241	GAACACACTA	CAGAAATGTAC	TGGCAGCAGC	CACGAAAAGA	AACTGCAACG	TCACACAGAT
6301	GAGGGAATTA	CCCACTTTGG	ACTCAGCAGT	ATTCAACGTG	GAGTGTTC	AAAAATTGCG
6361	ATGCAACCAA	GAATACTGGG	AAGAATTTGC	TGCCAGCCCT	ATTAGGATAA	CAACTGAGAA
6421	TTTAGCAACC	TATGTTACTA	AACTAAAAGG	GCCAAAAGCA	GCAGCGCTAT	TCGCAAAAC
6481	CCATAATCTA	CTGCCACTAC	AGGAAGTACC	AATGGATAGG	TTCACAGTAG	ATATGAAAAG
6541	GGACGTGAAG	GTGACTCCTG	GTACAAAGCA	TACAGAGGAA	AGACCTAAGG	TGCAGGTAT
6601	ACAGGCGGCT	GAACCCTTGG	CGACAGCATA	CCTATGTGGG	ATTCACAGAG	AGCTGGTTAG
6661	GAGGCTGAAC	GCCGTCCTCC	TACCCAATGT	ACATACACTA	TTTGACATGT	CTGCCGAGGA
6721	TTTCGATGCC	ATCATAGCCG	CACACTTTAA	GCCAGGAGAC	ACTGTTTTGG	AAACGGACAT
6781	AGCCTCCTTT	GATAAGAGCC	AAGACGATT	CCTTGCGCTT	ACTGCTTTGA	TGCTGTGAGA
6841	GGATTTAGGG	GTGGATCACT	CCCTGCTGGA	GTTGATAGAG	GCTGCTTTCG	GAGAGATTTT
6901	CAGCTGTCAC	CTACCGACAG	GTACGCGCTT	CAAGTTCGGC	GCCATGATGA	AATCAGGTAT
6961	GTTCTTAAC	CTGTTCGTCA	ACACATTGTT	AAACATCACC	ATCGCCAGCC	GAGTGCTGGA
7021	AGATCGTCTG	ACAAAATCCG	CGTGCGCGGC	CTTCATCGGC	GACGACAACA	TAATACATGG
7081	AGTCGTCTCC	GATGAATTGA	TGGCAGCCAG	ATGTGCCACT	TGGATGAACA	TGGAAGTGAA
7141	GATCATAGAT	GCAGTTGTAT	CCTTGAAAAG	CCCTTACTTT	TGTGGAGGGT	TTATACTGCA
7201	CGATACTGTG	ACAGGAACAG	CTTGACAGAT	GGCAGACCCG	CTAAAAAGGC	TTTTTAAACT
7261	GGGCAAACCG	CTAGCGGCAG	GTGACGAACA	AGATGAAGAT	AGAAGACGAG	CGCTGGCTGA
7321	CGAAGTGATC	AGATGGCAAC	GAACAGGGCT	AATTGATGAG	CTGGAGAAAG	CGGTATACTC
7381	TAGGTACGAA	GTGCAGGGTA	TATCAGTTGT	GGTAATGTCC	ATGGCCACCT	TTGCAAGCTC
7441	CAGATCCAAT	TTCGAGAAGC	TCAGAGGACC	CGTCATAACT	TTGTACGGCG	GTCTCTAAAT
7501	GGTACGCACT	ACAGCTACCT	ATTTTGCAGA	AGCCGACAGC	AAGTATCTAA	ACACTAATCA
7561	GCTACAATGG	AGTTCATCCC	AACCCAAACT	TTTTACAATA	GGAGGTACCA	GCCTCGACCC
7621	TGGACTCCGC	GCTCTACTAT	CCAAATCATC	AGGCCAGAC	CGCGCCCTCA	GAGGCAAGCT
7681	GGGCAACTTG	CCCAGCTGAT	CTCAGCAGTT	AATAAACTGA	CAATGCGCGC	GGTACCCCAA
7741	CAGAAGCCAC	GCAGGAATCG	GAAGAATAAG	AAGCAAAAGC	AAAAACAACA	GGCGCCACAA
7801	AACAACACAA	ATCAAAAAGAA	GCAGCCACCT	AAAAAGAAAC	CGGCTCAAAA	GAAAAAGAAG
7861	CCGGGCCGCA	GAGAGAGGAT	GTGCATGAAA	ATCGAAAATG	ATTGTATTTT	CGAAGTCAAG
7921	CACGAAGGTA	AGGTAACAGG	TTACGCGTGC	CTGGTGGGGG	ACAAAGTAAT	GAAACCAGCA
7981	CATGTAAAGG	GGACCATCGA	TAACGCGGAC	CTGGCCAAAC	TGGCCTTTAA	GCGGTCATCT
8041	AAGTATGACC	TTGAATGCGC	GCAGATACCC	GTGCACATGA	AGTCCGACGC	TTCAAGTTC
8101	ACCCATGAGA	AACCGGAGGG	GTACTACAAC	TGGCACCACG	GAGCAGTACA	GTACTCAGGA
8161	GGCCGGTTCA	CCATCCCTAC	AGGTGCTGGC	AAACCAGGGG	ACAGCGGCAG	ACCGATCTTC
8221	GACAACAAGG	GACGCGTGGT	GGCCATAGTC	TTAGGAGGAG	CTAATGAAGG	AGCCCGTACA
8281	GCCCTCTCGG	TGGTGACCTG	GAATAAAGAC	ATTGTCATA	AAATCACCCC	CGAGGGGGCC
8341	GAAGAGTGGA	GTCTTGCCAT	CCCAGTTATG	TGCCTGTTGG	CAAACACCAC	GTTCCCTGTC
8401	TCCCAGCCCC	CTTGACGCGC	CTGCTGCTAC	GAGAAGGAAC	CGGAGGAAAC	CCTACGCATG
8461	CTTGAGGACA	ACGTCATGAG	ACCTGGGTAC	TATCAGCTGC	TACAAGCATC	TTTAACATGT
8521	TCTCCCCACC	GCCAGCGACG	CAGCACCAAG	GACAACCTCA	ATGTCTATAA	AGCCACAAGA
8581	CCATACTTAG	CTCACTGTCC	CGACTGTGGA	GAAGGGCACT	CGTGCCATAG	TCCCGTAGCA

8641	CTAGAACGCA	TCAGAAATGA	AGCGACAGAC	GGGACGCTGA	AAATCCAGGT	CTCCTTGCAA
8701	ATCGGAATAA	AGACGGATGA	CAGCCACGAT	TGGACCAAGC	TGCGTTATAT	GGACAACCAC
8761	ATGCCAGCAG	ACGCAGAGAG	GGCGGGGCTA	TTTGTAAAGAA	CATCAGCACC	GTGTACGATT
8821	ACTGGAACAA	TGGGACACTT	CATCCTGGCC	CGATGTCCAA	AAGGGGAAAC	TCTGACGGTG
8881	GGATTCACTG	ACAGTAGGAA	GATTAGTCAT	TCATGTACGC	ACCCATTTCA	CCACGACCCT
8941	CCTGTGATAG	GTCGGGAAAA	ATTCCATTCC	CGACCGCAGC	ACGGTAAAGA	GCTACCTTGC
9001	AGCACGTACG	TGCAGAGCAC	CGCCGCAACT	ACCGAGGAGA	TAGAGGTACA	CATGCCCCCA
9061	GACACCCTCG	ATCGCACATT	AATGTCACAA	CAGTCCGGCA	ACGTAAAGAT	CACAGTCAAT
9121	GGCCAGACGG	TGCGGTATAA	GTGTAATTGC	GGTGGCTCAA	ATGAAGGACT	AACAACCTACA
9181	GACAAAGTGA	TTAATAACTG	CAAGGTTGAT	CAATGTCATG	CCGCGGTACC	CAATCACAAA
9241	AAGTGGCAGT	ATAACTCCCC	TCTGGTCCCG	CGTAATGCTG	AACTTGGGGA	CCGACAAGGA
9301	AAAATTACACA	TCCCGTTTCC	GCTGGCAAAAT	GTAACATGCA	GGGTGCCTAA	AGCAAGGAAC
9361	CCCACCGTGA	CGTACGGGAA	AAACCAAGTC	ATCATGCTAC	TGTATCCTGA	CCACCCAACA
9421	CTCCTGTCCT	ACCGGAATAT	GGGAGAAGAA	CCAAACTATC	AAGAAGAGTG	GGTGATGCAT
9481	AAGAAGGAAG	TCGTGCTAAT	CGTGCCGACT	GAAGGGCTCG	AGGTCACGTG	GGGCAACAAC
9541	GAGCCGTATA	AGTATTGGCC	GCAGTTATCT	ACAAACGGTA	CAGCCCATGG	CCACCCGCAT
9601	GAGATAATTC	TGTATTATTA	TGAGCTGTAC	CCTACTATGA	CTGTAGTAGT	TGTATCAGTG
9661	GCCACGTTCA	TACTCCTGTC	AATGGTGGGT	ATGGCAGCGG	GGATGTGCAT	GTGTGCACGA
9721	CGCAGATGCA	TCACACCGTA	TGAAGTGACA	CCAGGAGCTA	CCGTCCCTTT	CCTGCTTAGC
9781	CTAATATGCT	GCATCAGAAC	AGCTAAAGCG	GCCACATACC	AAGAGGCTGC	GATATACCTG
9841	TGGAACGAGC	AGCAACCTTT	GTTTTGGCTA	CAAGCCCTTA	TTCCGTGGC	AGCCCTGATT
9901	GTTCTATGCA	ACTGTCTGAG	ACTCTTACCA	TGCTGCTGTA	AAACGTTGGC	TTTTTTAGCC
9961	GTAATGAGCG	TCGGTGCCCA	CACTGTGAGC	GCGTACGAAC	ACGTAACAGT	GATCCCCGAAC
10021	ACGGTGGGAG	TACCGTATAA	GACTCTAGTC	AATAGACCTG	GCTACAGCCC	CATGGTATTG
10081	GAGATGGAAC	TACTGTCACT	CACCTTGGAG	CCAACACTAT	CGCTTGATTA	CATCAGGTGC
10141	GAGTACAAAA	CCGTCATCCC	GTCTCCGTAC	GTGAAGTGCT	GCGGTACAGC	AGAGTGCAAG
10201	GACAAAAACC	TACCTGACTA	CAGCTGTAAG	GTCTTCACCG	GCGTCTACCC	ATTTATGTGG
10261	GGCGGCGCCT	ACTGCTTCTG	CGACGCTGAA	AATACGCAGT	TGAGCGAAGC	ACATGTGGAG
10321	AAGTCCGAAT	CATGCAAAAC	AGAATTTGCA	TCAGCGTACA	GGGCTCATA	CGCATCTGCA
10381	TCAGCTAAGC	TCCGCGTCCT	TTACCAAGGA	AATAACATCA	CTGTAAGTGC	CTATGCAAAAC
10441	GGCGACCATG	CCGTCACAGT	TAAGGACGCC	AAATTCATTG	TGGGGCCAAT	GTCTTCAGCC
10501	TGGACACCTT	TCGACAACAA	AATTGTGGTG	TACAAAGGTG	ACGTCTATAA	CATGGACTAC
10561	CCGCCCTTTG	GCGCAGGAAG	ACCAGGACAA	TTTGCGGATA	TCCAAAGTCG	CACACCTGAG
10621	AGTAAAGACG	TCTATGCTAA	TACACAACCTG	GTACTGCAGA	GACCGGCTGT	GGGTACGGTA
10681	CACGTGCCAT	ACTCTCAGGC	ACCATCTGGC	TTTAAGTATT	GGCTAAAAGA	ACGCGGGGCG
10741	TACTGCAGC	ACACAGCACC	ATTTGGCTGC	CAAATAGCAA	CAAACCCGGT	AAGAGCGGTG
10801	AACTGCGCCG	TAGGGAACAT	GCCCCTCTCC	ATCGACATAC	CGGAAGCGGC	CTTCACTAGG
10861	GTCGTTCGACG	CGCCCTCTTT	AACGGACATG	TCGTGCGAGG	TACCAGCCTG	CACCCATTCC
10921	TCAGACTTTG	GGGGCGTCGC	CATTATTAAA	TATGCAGCCA	GCAAGAAAGG	CAAGTGTGCG
10981	GTGCATTTCGA	TGACTAACGC	CGTCACTATT	CGGGAAGCTG	AGATAGAAGT	TGAAGGGAAT
11041	TCTCAGCTGC	AAATCTCTTT	CTCGACGGCC	TTAGCCAGCG	CCGAATTCCG	CGTACAAGTC
11101	TGTTCTACAC	AAGTACACTG	TGCAGCTGAG	TGCCACCCCC	CGAAGGACCA	CATAGTCAAC
11161	TACCCGGCGT	CACATACCAC	CCTCGGGGTC	CAGGACATCT	CCGCTACGGC	GATGTCAATG
11221	GTGCAGAAGA	TCACGGGAGG	TGTGGGACTG	GTTGTTGCTG	TTGCCGCACT	GATTCTAATC
11281	GTGGTGCTAT	GCGTGTCGTT	CAGCAGGCAC	TAACCTTGACA	ATTAAGTATG	AAGGTATATG
11341	TGTCCCCTAA	GAGACACACT	GTACATAGCA	AATAATCTAT	AGATCAAAGG	GCTACGCAAC
11401	CCCTGAATAG	TAACAAAATA	CAAAATCACT	AAAAATTATA	AAAACAGAAA	AATACATAAA
11461	TAGGTATACG	TGTCCCCTAA	GAGACACATT	GTGTGTAGGT	GATAAGTATA	GA TCAAAGGG
11521	CCGAATAACC	CCTGAATAGT	AACAAAATAT	GAAAATCAAT	AAAAATCATA	AAATAGAAAA
11581	ACCATAAACA	GAAGTAGTTT	AAAGGGCTAT	AAAACCCCTG	AATAGTAACA	AAACATAAAG
11641	TTAATAAAAA	TCAAATGAAT	ACCATAATTG	GCAAACGGAA	GAGATGTAGG	TACTTAAGCT
11701	TCCTAAAGAGC	AGCCGAACCTC	ACTTTGAGAA	GTAGGCATAG	CATACCGAAC	TCTTCCACGA
11761	TTCTCCGAAC	CCACAGGGAC	GTAGGAGATG	TTATTTTGTT	TTTAATATTT	C

nsP1

nsP2

nsP3

nsP4

RSE

19 nt CSE

capsid

E3


E2

6k

E1

**Figure 3:** The genomic sequence of WT-CHK025 with the color-coding of each genetic element.

The result of phylogenetic analysis based on whole genome sequence using the neighbor-joining method calculated with CLC Sequence Viewer 6.6.1 program showed WT-CHK025 is classified in ECSA genotype, similar to other recent isolates in Thailand (Fig. 4).




**Figure 4:** Phylogenetic analysis of WT-CHK025 based on complete genome sequence.



### Tissue culture-adapted CHIKVs


To obtain tissue cultured-adapted CHIKV, WT-CHK025 was serially passaged in particular cell line. In addition, the virus was purified using plaque purification technique to get the virus that produces certain plaque morphology.

It was noticed that CHIKV produced from Vero cells showed larger plaque morphology when compared to its previous passage. So WT-CHK025 was subjected to the total of 17 passages alternating with 6 large plaque purifications in Vero cells resulting in CHIKV that produced uniformly large plaques, designated as CHK-L (Fig. 5).




**Figure 5:** Plaque morphology of Vero-adapted CHIKV. WT-CHK025 was undergone through 17 passages with 6 plaque purifications, resulting in CHK-L. WT-CHK025 and CHK-L were subjected to plaque assay and monitored at 4 dpi. P: passage; pp: plaque purification.

Since it was not possible to maintain the small plaque phenotype of CHIKV in Vero cells, the procedure to obtain the virus began with selecting the cell line that provides optimal condition for small plaque virus propagation. The 4th passage of WT-CHK025 was subjected to standard plaque assay for small plaque purification. After one small plaque was picked and propagated, this virus was used to infect three cell lines, Vero, MRC-5 and C6/36. The results showed that C6/36 cell produced more homogenous small plaques when compared to the others (fig.6).



**Figure 6:** Plaque morphology of CHIKV that was plaque purified for small plaque phenotype (A) then propagated in Vero (B), MRC-5 (C) and C6/36 (D) cells. The viruses were subjected to standard plaque assay and monitored at 7 dpi.


After propagated in C6/36 cells alternating with plaque purified for 3 times to the total of 14 passages, the virus showed the homogeneous small plaque phenotype and was designated as CHK-S (fig.7).



**Figure 7:** Plaque morphology of C6/36-adapted CHIKV. WT-CHK025 was undergone through 14 passages with 3 plaque purifications, resulting in CHK-S. WT-CHK025 and CHK-S were subjected to plaque assay and monitored at 7 dpi. P: passage; pp: plaque purification.

To compare parental and both tissue cultured-adapted CHIKVs in terms of the plaque morphology, WT-CHK025, CHK-L and CHK-S were subjected to the plaque assay in the same experiment. While WT-CHK025 produced plaques with different sizes, Vero-adapted CHK-L and C6/36 adapted CHK-S showed homogeneously large and small plaques, respectively (fig. 8).






**Figure 8:** Comparison of plaque morphology of WT-CHK025 (B and E), CHK-L (A and D) and CHK-S (C and F). The viruses were subjected to plaque assay and monitored on day 4 (A, B, C) or day 7 (D, E, F) post-infection.


#### **Phenotypic characterization of tissue culture-adapted CHIKVs**

The growth kinetics is one of the distinct phenotypic characters of each virus. However, due to the limited amount of WT-CHK025 virus, only tissue cultured-adapted viruses were used in this experiment. Single-step growth kinetics was performed in C6/36 cells and the viral titers were determined in Vero cells. Although both viruses reached the plateau phase in 18 hpi, CHK-L showed the maximum titer of log<sub>10</sub> pfu/ml whereas the maximum titer of CHK-S is approximately 1,000 times lower than that indicating the higher growing efficiency of CHK-L over CHK-S (fig.9).



**Figure 9:** Growth kinetics of CHK-L (opened circle) and CHK-S (opened triangle). C6/36 cells were infected with the viruses at MOI of 5. The supernatants were collected every 6 hours until 48 hpi and subjected to plaque assay in Vero cells in duplicate. The values are means from 2 independent experiments. The sample was done in duplicate for each experiment. The error bars indicate SD.

Next, the pathogenicities of the viruses were compared by mouse-neurovirulence study in suckling mice. Three groups of newborn mouse were intracranially injected with  $10^3$  pfu of WT-CHK025, CHK-L or CHK-S. The mice were kept for observation for 3 weeks and the numbers of survived mouse were used to plot survival curves (fig.10). Mice that received CHK-L succumbed to the infection from 4 dpi and only 17.8% of them survived by the end of the experiment. On the other hand, only one mouse of the group that infected with CHK-S was dead, making the survival rate of this group to be 98.2%. The group that got WT-CHK025 showed survival rate in between of those 2 groups with 74% of mouse survived at 21 dpi. In addition, the average survival times of the mice were calculated. The mice that infected WT-CHK025, CHK-L and CHK-S showed average survival times of 17.68, 8.18 and 20.82 days, respectively. These results indicate the correlation between CHIKV plaque size and pathogenicity in which the virus that produce large plaque is more pathogenic than the virus with small plaque.



**Figure 10:** Mouse neurovirulence of CHIKVs. Three groups of suckling mouse were intracranially infected with WT-CHK025 (cross), CHK-L (opened circle) or CHK-S (opened triangle). Mice were observed for survival for 21 days. The graph showed percentage of survived mouse.

### Genotypic characterization of tissue culture-adapted CHIKVs

The whole genomes of CHK-L and CHK-S were sequenced as described in the previous section. The resulting sequences were compared to WT-CHK025 sequence.

Seven nucleic acid differences between the genome of WT-CHK025 and CHK-L were found at 5'NTR, nsP1, nsP2, nsP3, E2 and 3'NTR regions, resulting in 5 amino acid differences. To confirm these differences, two additional clones of large plaque purified-Vero adapted CHIKV were sequenced at those particular regions. The result showed 4 consensus mutations, which lead to 4 amino acid changes at nsP1: G230R, nsP2: P618L, nsP3: G117R and E2: N187K (table 3).

**Table 3** Differences between WT-CHK025 and 3 clones of CHK-L when complete genomic sequences were compared.

Gene/ position	virus	Nucleotide s	Amino acid	Nucleotides and amino acid comparison	WT	L-17	L-17/2	L17/3
nsP1 134	WT	<u>I</u> GC	C		C	S	C	C
	Large	<u>A</u> GC	S		<u>I</u> GC	<u>A</u> GC	<u>I</u> GC	<u>I</u> GC
nsP1 230	WT	<u>G</u> GG	G		G	R	R	R
	Large	<u>A</u> GG	R		<u>G</u> GG	<u>A</u> GG	<u>A</u> GG	<u>A</u> GG
nsP2 618	WT	C <u>C</u> A	P		P	L	L	L
	Large	C <u>T</u> A	L		C <u>C</u> A	C <u>T</u> A	C <u>T</u> A	C <u>T</u> A
nsP3 117	WT	<u>G</u> GG	G		G	R	R	R
	Large	<u>A</u> GG	R		<u>G</u> GG	<u>A</u> GG	<u>A</u> GG	<u>A</u> GG
E2 187	WT	AA <u>C</u>	N		N	K	K	K
	Large	AA <u>A</u>	K		AA <u>C</u>	AA <u>A</u>	AA <u>A</u>	AA <u>A</u>
5' NTR	WT	A	-		A	G	A	A
	Large	G	-					
3' NTR	WT	A	-		A	G	A	A
	Large	G	-					

The nucleotide sequence alignment between WT-CHK025 and CHK-S showed 4 nucleotide differences in nsP1, nsP2 and nsP3, which are consensus in all 3 clones of CHK-S. However, the changes in nsP2:761 (A→G) and nsP3:39 (A→G) resulted in synonymous mutations while one mutation in nsP1 turned out to be the same mutation as CHK-L. Therefore, the mutation that might responsible for the small plaque phenotype remain only at position 546 of nsP2 in which Aspartic acid is changed to Glycine (table 4).

**Table 4** Differences between WT-CHK025 and 3 clones of CHK-S when complete genomic sequences were compared.

Gene/ position	virus	Nucleotides	Amino acid	Nucleotides and amino acid comparison	WT	S14	S14/2	S14/3
nsP1 230	WT	<u>G</u> GG	G		G	R	R	R
	Small	<u>A</u> GG	R		<u>G</u> GG	<u>A</u> GG	<u>A</u> GG	<u>A</u> GG
nsP2 546	WT	G <u>A</u> T	D		D	G	G	G
	Small	G <u>G</u> T	G		G <u>A</u> T	G <u>G</u> T	G <u>G</u> T	G <u>G</u> T
nsP2 761	WT	GA <u>A</u>	E		E	E	E	E
	Small	GAG <u>G</u>	E		GA <u>A</u>	GAG <u>G</u>	GAG <u>G</u>	GAG <u>G</u>
nsP3 39	WT	AA <u>A</u>	K		K	K	K	K
	Small	AA <u>G</u>	K		AA <u>A</u>	AA <u>G</u>	AA <u>G</u>	AA <u>G</u>

In summary, 3 mutations in nsP2, nsP3 and E2 might be responsible for large plaque phenotype while only single mutation in nsP2 seemed to be determinant of small plaque. The nsP1: G230R seemed to be the tissue culture adapted mutation since this mutation is present in both CHK-L and CHK-S (table 5).

**Table 5** Summary of amino acid differences among WT-CHK025, CHK-L and CHK-S.

aa position	Gene	WT-CHK025	CHK-L	CHK-S
230	nsP1	G <u>GGG</u>	R <u>AGG</u>	R <u>AGG</u>
546	nsP2	D <u>GAT</u>	D <u>GAT</u>	G <u>GGT</u>
618	nsP2	P <u>CCA</u>	L <u>CTA</u>	P <u>CCA</u>
117	nsP3	G <u>GGG</u>	R <u>AGG</u>	G <u>GGG</u>
187	E2	N <u>AAC</u>	K <u>AAA</u>	N <u>AAC</u>



## สรุปและวิจารณ์ผลการทดลอง

The complete genomic sequence of CHIKV clinical isolate, WT-CHK025, was determined. The length of the genome is 11,811 bp. Phylogenetic analysis revealed this virus is classified in ECSA genotype based on whole genome sequence analysis and amino acid position 226 of E1 protein is Valine, which is similar to other CHIKV isolates from the recent outbreaks in Thailand and neighboring countries. In the previous study, E1:A226V mutation was suggested to enhance viral vector adaptation to *A.albopictus*. This could be a major factor leading to an epidemic in the area that is predominated by *A.albopictus* including the southern part of Thailand.

Through serially passages and plaque purifications, CHIKV was tissue cultured-adapted in mammalian cells, Vero, and mosquito cells, C6/36, resulting in large and small plaque viruses, respectively. Vero cells are capable of adapting the virus to produce large plaque. In addition to our result, other study also showed that Vero cell adapted-enterovirus 71 produced larger plaque size than the original enterovirus 71. In contrast, C6/36 cells showed the ability to stabilize the small plaque morphology of the virus.

The viruses with different plaque morphology also display different degrees of virulent in mouse. Percentages of the survived suckling mouse after infected with WT-CHK025, CHK-S and CHK-L are 74.0%, 98.2% and 15.6%, respectively. CHK-L shows the highest pathogenicity while CHK-S is almost nonpathogenic. Our result also concurs with the general acceptance that the virus with larger plaque size is more pathogenic than the virus with smaller one.

Comparison of entire genomic sequences of WT-CHK025 and CHK-L reveals 3 mutations at nsP2: P618L, nsP3: G117R and E2: N187K. Previous report showed that a point mutation in the protease domain of nsP2 could affect the infectivity and pathogenesis of sindbis virus (SINV), the other virus in the same *Alphavirus* family. The nsP2: P618L mutation is also located in nsP2 protease domain. Hence, this change from proline to leucine might be able to alter the infectivity, resulting in large plaque phenotype.

The nsP3: G117R mutation is located in the macro domain, which is believed to display an ADP-ribose binding capacity. The RNA binding property can be enhanced by the presence of positively charged patches of amino acid at protein surface or outside of the active site pocket of this domain. The mutation increases positive charge of this macro domain, which might lead to an increase in ADP-ribose binding activity and consequently increase viral transcription. Moreover, nsP3 macro domain was shown to be significant in an age-dependent susceptibility of mice to SINV encephalomyelitis. Thereby, this mutation might also involve in the increase of viral pathogenicity.

The viral E2 protein functions as a receptor binding protein. Previous study in chimeric alphaviruses suggested that the mutations in E2 that increase positive charge of the protein can enhance the binding of the protein to heparan sulfate, one of the putative alphavirus receptor, which lead to more efficient viral entry. E2: N187K mutation, which increases positive charge of CHK-L, might also work the same way in enhancing the viral entry and lead to the enlarge plaque.

Only one nonsynonymous mutation of CHK-S was identified, nsP2: D546G. This mutation is located in the nsP2 protease domain, very close to catalytic site of the protein. The nsP2 amino acid residues 546, 547 and 548 of CHIKV (or 544, 545 and 546 of VEEV crystal structure) form a thumb that regulate grooved binding and it is also responsible for substrate specificity of nsP2 protease enzyme. The efficiency of the protease activity of nsP2 has a high impact on the viral replication since the processes in viral RNA replication depend largely on the cleavage of the viral replication complex. Therefore, any change that might interrupt the protease activity will alter the viral replication as well. However, the contribution of these mutations on the viral phenotype has to be confirmed by reverse genetics.